Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 12/20 | 0.41 |
| ▸ | NPY1R | P25929 | 6/20 | 0.41 |
| ▸ | NPY2R | P49146 | 4/20 | 0.41 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.41 |
| ▸ | FNTA | P49354 | 6/20 | 0.35 |
| ▸ | FNTB | P49356 | 6/20 | 0.35 |
| ▸ | PGGT1B | P53609 | 6/20 | 0.35 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32690582 | 0.87 | NPY4R (0.46) | NPY4RNPY1RNPY2RNPY5RDPP7 | |
| SCHEMBL30811126 | 0.85 | NPY4R (0.42) | NPY4RNPY1RNPY2RNPY5RFNTA | |
| SCHEMBL31520395 | 0.85 | NPY4R (0.40) | NPY4RNPY1RNPY2RNPY5RFNTA | |
| SCHEMBL29658167 | 0.83 | NPY4R (0.45) | NPY4RNPY1RNPY2RNPY5RFNTA | |
| SCHEMBL23091326 | 0.83 | NPY4R (0.44) | NPY4RNPY1RNPY2RNPY5RFNTA | |
| SCHEMBL8067094 | 0.83 | NPY4R (0.44) | NPY4RNPY1RNPY2RNPY5RFNTA | |
| SCHEMBL21828618 | 0.83 | NPY4R (0.44) | NPY4RNPY1RNPY2RNPY5RFNTA | |
| SCHEMBL29947092 | 0.83 | NPY4R (0.44) | NPY4RNPY1RNPY2RNPY5RFNTA | |
| SCHEMBL31097081 | 0.82 | NPY4R (0.51) | NPY4RNPY1RNPY2RNPY5RFNTA | |
| SCHEMBL29498231 | 0.81 | PTGS1 (0.53) | NPY4RNPY1RNPY2RNPY5RFNTA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240391954-A1 | MC4R AGONIST PEPTIDES | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2024-11-28 | — | — | US | disclosed |
| EP-4392072-A1 | MC4R AGONIST PEPTIDES | The Regents Of The University Of Michigan (US) | 2024-07-03 | — | — | EP | disclosed |
| WO-2023028538-A1 | MC4R AGONIST PEPTIDES | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2023-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240391954-A1 | MC4R AGONIST PEPTIDES | MC4R, MC3R, MC5R | NPY4R 6/4885NPY1R 9/4885NPY2R 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.